The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | L | Antineoplastic and immunomodulating agents | |
| 2 | L01 | Antineoplastic agents | |
| 3 | L01C | Plant alkaloids and other natural products | |
| 4 | L01CD | Taxanes |
| Code | Title | |
|---|---|---|
| L01CD01 | Paclitaxel | |
| L01CD02 | Docetaxel | |
| L01CD03 | Paclitaxel poliglumex | |
| L01CD04 | Cabazitaxel | |
| L01CD51 |
| Active Ingredient | Description | |
|---|---|---|
| Cabazitaxel |
Cabazitaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells. Cabazitaxel binds to tubulin and promotes the assembly of tubulin into microtubules while simultaneously inhibiting their disassembly. |
|
| Docetaxel |
Docetaxel is an antineoplastic agent which acts by promoting the assembly of tubulin into stable microtubules and inhibits their disassembly which leads to a marked decrease of free tubulin. |
|
| Paclitaxel |
Paclitaxel is an antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilises microtubules by preventing depolymerisation. This stability results in the inhibition of the normal dynamic reorganisation of the microtubule network that is essential for vital interphase and mitotic cellular functions. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| ABRAXANE Powder for suspension for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| ANZATAX Concentrate for solution for injection | Pharmaceutical Benefits Scheme (AU) | MPI, EU: SmPC | |
| APEALEA Powder for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| EBETAXEL Concentrate for solution for infusion | Health Products Regulatory Authority (IE) | MPI, EU: SmPC | |
| JEVTANA Concentrate and solvent for solution for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| NAVERUCLIF Powder for dispersion for infusion | European Medicines Agency (EU) | MPI, EU: SmPC | |
| Taxotere 20mg/1ml concentrate for solution for infusion | Medicines & Healthcare Products Regulatory Agency (GB) | MPI, EU: SmPC |
